PHARMACEUTICAL 2020

Macrogenics INC
Rank 134 of 363



PHARMACEUTICAL 2020

Macrogenics INC
Rank 134 of 363

The relative strengths and weaknesses of Macrogenics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Macrogenics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 45% points.The greatest weakness of Macrogenics INC is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 49% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	239,785
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	45,167
Liabilities, Non-Current	27,553
Other Assets	24,505
Other Compr. Net Income	19
Other Expenses	0
Other Liabilities	9,153
Other Net Income	25,374
Other Revenues	64,188
Property and Equipment	48,211
Research and Development	195,309
Selling, General and Administrative Expense	46,064

Output Variable	Value in 1000 USD
Assets	312,501
Liabilities	81,873
Expenses	241,373
Revenues	64,188
Stockholders Equity	230,628
Net Income	-151,811
Comprehensive Net Income	-151,802
BaseVar	362,664
ECR before LimitedLiability	178%
Economic Capital Ratio	287%